Lantheus Holdings, Inc. Research and Development Expense
Lantheus Holdings, Inc. (LNTH) reported Research and Development Expense of $38.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Lantheus Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $38.20M, a 16.02% decline year-over-year.
- Lantheus Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $39.38M, a 8.44% increase year-over-year.
- Lantheus Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $47.48M, a 34.41% increase year-over-year.
- Lantheus Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $48.02M, a 98.88% increase year-over-year.
- Lantheus Holdings, Inc. research and development expense for fiscal 2025 was $177.31M, a 5.48% increase from fiscal 2024.
- Lantheus Holdings, Inc. research and development expense for fiscal 2024 was $168.10M, a 116.32% increase from fiscal 2023.
- Lantheus Holdings, Inc. research and development expense for fiscal 2023 was $77.71M, a 75.07% decline from fiscal 2022.
- Lantheus Holdings, Inc. research and development expense for fiscal 2022 was $311.68M, a 593.15% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.20M 10-Q · filed 2026-08-06 | $77.58M 10-Q · filed 2026-08-06 | $125.06M derived: sum of 3 quarters · filed 2026-08-06 | $173.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $39.38M 10-Q · filed 2026-05-07 | $86.86M derived: sum of 2 quarters · filed 2026-05-07 | $134.88M derived: sum of 3 quarters · filed 2026-05-07 | $180.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $47.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.50M derived: sum of 2 quarters · filed 2026-02-26 | $140.99M derived: sum of 3 quarters · filed 2026-08-06 | $177.31M 10-K · filed 2026-02-26 |
| 2025-09-30 | $48.02M 10-Q · filed 2025-11-06 | $93.51M derived: sum of 2 quarters · filed 2026-08-06 | $129.83M 10-Q · filed 2025-11-06 | $165.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $45.49M 10-Q · filed 2026-08-06 | $81.80M 10-Q · filed 2026-08-06 | $117.13M derived: sum of 3 quarters · filed 2026-08-06 | $141.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $36.31M 10-Q · filed 2026-05-07 | $71.64M derived: sum of 2 quarters · filed 2026-05-07 | $95.79M derived: sum of 3 quarters · filed 2026-05-07 | $156.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $35.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.47M derived: sum of 2 quarters · filed 2026-02-26 | $120.07M derived: sum of 3 quarters · filed 2026-02-26 | $168.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $24.15M 10-Q · filed 2025-11-06 | $84.75M derived: sum of 2 quarters · filed 2025-11-06 | $132.77M 10-Q · filed 2025-11-06 | $149.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $60.60M 10-Q · filed 2025-08-06 | $108.63M 10-Q · filed 2025-08-06 | $125.45M derived: sum of 3 quarters · filed 2026-02-26 | $139.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $48.02M 10-Q · filed 2025-05-07 | $64.85M derived: sum of 2 quarters · filed 2026-02-26 | $79.30M derived: sum of 3 quarters · filed 2026-02-26 | $95.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $16.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.27M derived: sum of 2 quarters · filed 2026-02-26 | $47.17M derived: sum of 3 quarters · filed 2026-02-26 | $77.71M 10-K · filed 2026-02-26 |
| 2023-09-30 | $14.45M 10-Q · filed 2024-11-06 | $30.35M derived: sum of 2 quarters · filed 2024-11-06 | $60.88M 10-Q · filed 2024-11-06 | $333.11M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $15.90M 10-Q · filed 2024-07-31 | $46.43M 10-Q · filed 2024-07-31 | $318.66M derived: sum of 3 quarters · filed 2025-02-26 | $331.18M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $30.53M 10-Q · filed 2024-05-02 | $302.76M derived: sum of 2 quarters · filed 2025-02-26 | $315.27M derived: sum of 3 quarters · filed 2025-02-26 | $330.01M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $272.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $284.74M derived: sum of 2 quarters · filed 2025-02-26 | $299.48M derived: sum of 3 quarters · filed 2025-02-26 | $311.68M 10-K · filed 2025-02-26 |
| 2022-09-30 | $12.52M 10-Q · filed 2023-11-02 | $27.25M derived: sum of 2 quarters · filed 2023-11-02 | $39.45M 10-Q · filed 2023-11-02 | $50.75M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $14.73M 10-Q · filed 2023-08-03 | $26.94M 10-Q · filed 2023-08-03 | $38.23M derived: sum of 3 quarters · filed 2024-02-22 | $49.48M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $12.20M 10-Q · filed 2023-05-04 | $23.50M derived: sum of 2 quarters · filed 2024-02-22 | $34.75M derived: sum of 3 quarters · filed 2024-02-22 | $46.81M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $11.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $22.55M derived: sum of 2 quarters · filed 2024-02-22 | $34.61M derived: sum of 3 quarters · filed 2024-02-22 | $44.97M 10-K · filed 2024-02-22 |
| 2021-09-30 | $11.25M 10-Q · filed 2022-11-03 | $23.31M derived: sum of 2 quarters · filed 2022-11-03 | $33.67M 10-Q · filed 2022-11-03 | $46.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $12.06M 10-Q · filed 2022-08-04 | $22.42M 10-Q · filed 2022-08-04 | $35.06M derived: sum of 3 quarters · filed 2023-02-23 | $46.74M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $10.36M 10-Q · filed 2022-04-29 | $23.00M derived: sum of 2 quarters · filed 2023-02-23 | $34.68M derived: sum of 3 quarters · filed 2023-02-23 | $39.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $24.32M derived: sum of 2 quarters · filed 2023-02-23 | $28.74M derived: sum of 3 quarters · filed 2023-02-23 | $32.79M 10-K · filed 2023-02-23 |
| 2020-09-30 | $11.68M 10-Q · filed 2021-11-04 | $16.10M derived: sum of 2 quarters · filed 2021-11-04 | $20.15M 10-Q · filed 2021-11-04 | $24.58M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $4.42M 10-Q · filed 2021-07-28 | $8.47M 10-Q · filed 2021-07-28 | $12.90M derived: sum of 3 quarters · filed 2022-02-24 | $17.76M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $4.05M 10-Q · filed 2021-05-04 | $8.48M derived: sum of 2 quarters · filed 2022-02-24 | $13.34M derived: sum of 3 quarters · filed 2022-02-24 | $19.14M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $9.29M derived: sum of 2 quarters · filed 2022-02-24 | $15.09M derived: sum of 3 quarters · filed 2022-02-24 | $20.02M 10-K · filed 2022-02-24 |
| 2019-09-30 | $4.86M 10-Q · filed 2020-11-05 | $10.65M derived: sum of 2 quarters · filed 2020-11-05 | $15.58M 10-Q · filed 2020-11-05 | $20.14M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $5.79M 10-Q · filed 2020-07-31 | $10.72M 10-Q · filed 2020-07-31 | $15.28M derived: sum of 3 quarters · filed 2021-02-25 | $19.59M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $4.93M 10-Q · filed 2020-04-30 | $9.48M derived: sum of 2 quarters · filed 2021-02-25 | $13.80M derived: sum of 3 quarters · filed 2021-02-25 | $18.01M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $8.87M derived: sum of 2 quarters · filed 2021-02-25 | $13.08M derived: sum of 3 quarters · filed 2021-02-25 | $17.07M 10-K · filed 2021-02-25 |
| 2018-09-30 | $4.32M 10-Q · filed 2019-10-31 | $8.53M derived: sum of 2 quarters · filed 2019-10-31 | $12.52M 10-Q · filed 2019-10-31 | $16.50M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $4.21M 10-Q · filed 2019-07-25 | $8.20M 10-Q · filed 2019-07-25 | $12.18M derived: sum of 3 quarters · filed 2020-02-25 | $15.73M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $3.99M 10-Q · filed 2019-04-30 | $7.96M derived: sum of 2 quarters · filed 2020-02-25 | $11.52M derived: sum of 3 quarters · filed 2020-02-25 | $16.76M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $7.53M derived: sum of 2 quarters · filed 2020-02-25 | $12.77M derived: sum of 3 quarters · filed 2020-02-25 | $18.13M 10-K · filed 2020-02-25 |
| 2017-09-30 | $3.55M 10-Q · filed 2018-10-30 | $8.80M derived: sum of 2 quarters · filed 2018-10-30 | $14.15M 10-Q · filed 2018-10-30 | $17.86M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-06-30 | $5.24M 10-Q · filed 2018-08-01 | $10.60M 10-Q · filed 2018-08-01 | $14.30M derived: sum of 3 quarters · filed 2019-02-20 | $17.15M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-03-31 | $5.35M 10-Q · filed 2018-05-02 | $9.06M derived: sum of 2 quarters · filed 2019-02-20 | $11.91M derived: sum of 3 quarters · filed 2019-02-20 | $14.52M derived: sum of 4 quarters · filed 2019-02-20 |
| 2016-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $6.56M derived: sum of 2 quarters · filed 2019-02-20 | $9.17M derived: sum of 3 quarters · filed 2019-02-20 | $12.20M 10-K · filed 2019-02-20 |
| 2016-09-30 | $2.85M 10-Q · filed 2017-11-02 | $5.46M derived: sum of 2 quarters · filed 2017-08-01 | $8.49M 10-Q · filed 2017-11-02 | $11.56M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $2.61M 10-Q · filed 2017-08-01 | $5.64M 10-Q · filed 2017-08-01 | $8.71M derived: sum of 3 quarters · filed 2018-02-26 | $11.17M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $3.04M 10-Q · filed 2017-05-02 | $6.10M derived: sum of 2 quarters · filed 2018-02-26 | $8.56M derived: sum of 3 quarters · filed 2018-02-26 | $11.20M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $5.52M derived: sum of 2 quarters · filed 2018-02-26 | $8.16M derived: sum of 3 quarters · filed 2018-02-26 | $14.36M 10-K · filed 2018-02-26 |
| 2015-09-30 | $2.46M 10-Q · filed 2016-11-01 | $5.10M derived: sum of 2 quarters · filed 2016-11-01 | $11.29M 10-Q · filed 2016-11-01 | $16.01M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $2.64M 10-Q · filed 2016-08-04 | $8.83M 10-Q · filed 2016-08-04 | $13.55M derived: sum of 3 quarters · filed 2017-02-23 | $16.60M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $6.20M 10-Q · filed 2016-05-03 | $10.91M derived: sum of 2 quarters · filed 2017-02-23 | $13.96M derived: sum of 3 quarters · filed 2017-02-23 | $16.65M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $7.76M derived: sum of 2 quarters · filed 2017-02-23 | $10.45M derived: sum of 3 quarters · filed 2017-02-23 | $13.67M 10-K · filed 2017-02-23 |
| 2014-09-30 | $3.05M 10-Q · filed 2015-11-04 | $5.74M derived: sum of 2 quarters · filed 2015-11-04 | $8.96M 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $2.69M 10-Q · filed 2015-08-05 | $5.91M 10-Q · filed 2015-08-05 | ||
| 2013-12-31 | $30.46M 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |